Sharon Bio-Medicine Ltd - Stock Valuation and Financial Performance

BSE: 532908 | NSE: SHARONBIO | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on Sharon Bio-Medicine

M-Cap below 100cr DeciZen not available

Sharon Bio-Medicine stock performance -

mw4me loader
P/E Ratio (SA):
0.10
Market Cap:
1.9 Cr.
52-wk low:
3.1
52-wk high:
4.7

Is an attractive stock to invest in?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

The key valuation ratios of Sharon Bio-Medicine Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is a good buy now?

No data found

10 Year X-Ray of Sharon Bio-Medicine:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

Jun'09Jun'10Jun'11Jun'12Jun'13Jun'14Jun'15Mar'16Mar'22Mar'23TTM
ROCE % 8.8%8.4%9.9%10.6%10.5%11.3%-10.6%-25%3.9%8%-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 4204976067851,0601,314834338188195190
Sales YoY Gr.-18.3%22.1%29.5%35%24%-36.5%-59.5%-44.3%3.5%-
Adj EPS 1.81.933.956.6-14.5-27.929.231.433
YoY Gr.-4.9%53.4%33.1%27.2%31.5%-319.7%NANA7.5%-
BVPS (₹) 9.310.913.613.117.924.18-22.9-1,130-1,096.4-1,161.5
Adj Net
Profit
19.420.331.341.652.969.6-172-33216.81819
Cash Flow from Ops. -50.1-28.1-36-53-70.2-69.5-81.9-37.62341.1-
Debt/CF from Ops. -5.2-12.2-9.6-9.6-9.2-10.4-10.1-29.73620.1-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -8.2%-28.7%-38.4%3.5%
Adj EPS 37%44.3%NA7.5%
BVPS-270%-327.8%-616%NA
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Jun'09Jun'10Jun'11Jun'12Jun'13Jun'14Jun'15Mar'16Mar'22Mar'23TTM
Return on
Equity %
2017.819.521.324.223.7-74.6786.2-4.3-3-2.9
Op. Profit
Mgn %
9.610.511.712.111.412-4.1-52.813.913.213.3
Net Profit
Mgn %
4.64.15.25.355.3-20.7-98.38.99.310
Debt to
Equity
2.732.43.73.42.98.7-4.1-1.3-1.3-
Working Cap
Days
168190198203198202322761491194161
Cash Conv.
Cycle
14116417016716516927265732233-160

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Sharon Bio-Medicine Ltd.

Standalone Consolidated
TTM EPS (₹) 33 -406.4
TTM Sales (₹ Cr.) 190 838
BVPS (₹.) -1,161.5 -394.2
Reserves (₹ Cr.) -670 -228
P/BV 0.00 -0.01
PE 0.10 0.00
From the Market
52 Week Low / High (₹) 3.10 / 4.65
All Time Low / High (₹) 2.60 / 90.20
Market Cap (₹ Cr.) 1.9
Equity (₹ Cr.) 1.2
Face Value (₹) 2
Industry PE 48.2

Management X-Ray of Sharon Bio-Medicine:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Sharon Bio-Medicine

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSJun'09Jun'10Jun'11Jun'12Jun'13Jun'14Jun'15Mar'16Mar'22Mar'23
Sales419.79496.50606.05785.061,059.501,313.77833.95253.45188.39194.98
Operating Expenses 380.89446.65535.39689.78939.011,156.71868.34387.29162.19169.63
Manufacturing Costs4.909.319.519.9710.7412.4319.4714.1117.8317.68
Material Costs364.78419.09504.80655.97902.081,112.75808.50332.2595.2495.36
Employee Cost 5.539.4112.6513.9714.3118.8719.8316.5530.5933.29
Other Costs 5.698.848.439.8711.8812.6620.5524.3918.5223.30
Operating Profit 38.9049.8570.6695.28120.49157.06-34.38-133.8426.2025.35
Operating Profit Margin (%) 9.3%10.0%11.7%12.1%11.4%12.0%-4.1%-52.8%13.9%13.0%
Other Income 1.831.571.120.930.891.682.631.952.814.46
Interest 14.362126.8134.2643.0658.6393.6470.980.110.06
Depreciation 4.186.408.348.8612.1315.3519.1715.0111.2310.74
Exceptional Items 00-0.16-0.0300-76.64-71.3500
Profit Before Tax 22.1924.0236.4753.0566.1984.75-221.20-289.2417.6719.01
Tax 3.595.315.3111.4413.3315.144.669.9700
Profit After Tax 18.6018.7231.1741.6152.8669.62-225.86-299.2017.6719.01
PAT Margin (%) 4.4%3.8%5.1%5.3%5.0%5.3%-27.1%-118.0%9.4%9.7%
Adjusted EPS (₹)1.81.83.03.95.06.6-19.0-25.230.733.0
Dividend Payout Ratio (%)7%8%6%5%3%5%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSJun'09Jun'10Jun'11Jun'12Jun'13Jun'14Jun'15Mar'16Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 98.10114.97143.91138.17189.18263.39104.36-195.21-609.22-590.34
Share Capital 10.5610.5610.5610.5610.5621.1123.7923.791.151.15
Reserves 87.54104.41133.35127.61178.62242.2780.57-219-610.37-591.50
Minority Interest0000000000
Debt262.41342.56343.62507.54643.89725.38824.41836.32827.32827.32
Long Term Debt262.41342.56130.79238.64280.87291.42522.57543.60558.02558.02
Short Term Debt00212.83268.89363.02433.96301.84292.72269.31269.31
Trade Payables22.6526.3031.0549.6759.8661.1751.2740.0343.4640.48
Others Liabilities 14.1417.0267.3678.6579.01111.6931.4841.7037.5735.58
Total Liabilities 397.30500.86585.94774.03971.931,161.631,011.53722.84299.14313.04

Fixed Assets

Gross Block67.06201.11206.42235.62317.87380.87406.69408.15398.66473.46
Accumulated Depreciation10.9417.3425.5734.2946.3355.8574.5889.60264.02345.59
Net Fixed Assets56.12183.77180.85201.33271.55325.02332.10318.56134.64127.87
CWIP 106.9122.7427.0459.9042.8214.93000.150.20
Investments 1.294.133.883.983.981.231.040.0600
Inventories89.66116.67155.21196.22260.24322.45301.42179.9942.3339.02
Trade Receivables133.46158.77192.54260.12355.10414.31315.02183.1826.8826.08
Cash Equivalents 3.352.393.846.286.2712.2716.0110.1651.6389.99
Others Assets6.5212.3922.5946.2031.9871.4145.9430.9043.5129.88
Total Assets 397.30500.86585.94774.03971.931,161.631,011.53722.84299.14313.04

Cash Flow

(All Figures are in Crores.)
PARTICULARSJun'09Jun'10Jun'11Jun'12Jun'13Jun'14Jun'15Mar'16Mar'22Mar'23
Cash Flow From Operating Activity -50.06-28.10-36-52.98-70.23-69.47-81.91-28.2122.9641.11
PBT 22.1924.0236.4753.0566.1984.75-144.56-217.8917.6719.01
Adjustment 13.6522.3729.9432.6841.9259.2031.964.0410.138.44
Changes in Working Capital -71.54-53.49-75.6-104.73-135.56-154.8124.34256.62-5.1913.13
Tax Paid 0000000000
Cash Flow From Investing Activity -66.04-51.16-8.24-61.24-64.28-27.38-10.060.14-3.24-2.77
Capex -70.99-49.89-9.62-62.07-65.17-31.81-10.89-1.47-4.51-4.99
Net Investments 3.12-2.840.25-0.1002.750.200.9700
Others 1.831.571.120.930.891.680.630.641.262.21
Cash Flow From Financing Activity 46.8478.3045.69116.66134.50102.8595.7022.220.030.02
Net Proceeds from Shares 0.36046.7400066.83000
Net Proceeds from Borrowing 0000000000
Interest Paid 0000000000
Dividend Paid -1.27-1.58-1.90-1.90-1.58-3.800000
Others 47.7479.890.85118.56136.08106.6528.8722.220.030.02
Net Cash Flow -69.27-0.961.452.44-0.0163.73-5.8519.7438.36
PARTICULARSJun'09Jun'10Jun'11Jun'12Jun'13Jun'14Jun'15Mar'16Mar'22Mar'23
Ratios
ROE (%)20.8717.6324.1529.5832.3731.44-129.46N/AN/AN/A
ROCE (%)10.8910.8112.5714.0613.7614.73-12.8N/AN/AN/A
Asset Turnover Ratio1.161.111.121.151.211.230.770.290.370.64
PAT to CFO Conversion(x)-2.69-1.5-1.15-1.27-1.33-1N/AN/A1.32.16
Working Capital Days
Receivable Days9910710610510610716035920350
Inventory Days64768282798113734721576
Payable Days2421212222202550160161

Sharon Bio-Medicine Ltd Stock News

Sharon Bio-Medicine Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Sharon Bio-Medicine on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Sharon Bio-Medicine stood at ₹1.85.
The latest P/E ratio of Sharon Bio-Medicine as of 01-Jan-1970 05:30 is 0.10.
The latest P/B ratio of Sharon Bio-Medicine as of 01-Jan-1970 05:30 is 0.00.
The 52-week high of Sharon Bio-Medicine is ₹4.65 and the 52-week low is ₹3.10.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sharon Bio-Medicine is ₹190.2 ( Cr.) .

About Sharon Bio-Medicine Ltd

Sharon Bio-Medicine, established in 1989, is into manufacturing and supply of Active Pharmaceutical Ingredients (APIs).

The company has established its name as a reliable supplier of intermediates. In international markets, the company serves Latin America, Middle East, South East Asia and SAARC countries. With the setting up of new facilities Sharon has geared up to enter other markets such as Europe, Japan, Australia and USA in the next two years.

With setting and successful commercialisation of the solid dosage formulation facility at Dehradun, its formulations are now being marketed in Africa, Latin America and other markets.

The company’s research team constantly seeks development of non-infringing routes for APIs in therapeutic segments like cardiovascular diseases and anti-ulcerants.

It also offers contract manufacturing for finished dosage forms; viz. tablets, capsules and injectables. Sharon has identified niche areas of oncology for export markets.

Products

  • APIs and Pellets
  • Intermediates
  • Formulations

Milestones

  • 1995 - The current management took over and started manufacturing of pharma intermediates
  • 1997 - The company started manufacturing APIs and launched its first drug -- trimetazidine di hydrochloride -- a cardiovascular drug.
  • 2000 - The company came out with public offering of 25% stake. The issue was oversubscribed by 3.85 times. It set up a R&D block to carry out process synthesis for APIs and intermediates.
  • 2005 - The company received ISO 9001-2000 accreditation by BVQI-UKAS and BVQI-ANAB
  • 2006 - It started construction of a state-of-the-art formulation unit for oral solid dosages at Dehradun, New Delhi with an estimated cost of $8 million.
  • 2007 - The company commissioned its formulation plant. It also started supplying formulations to reputed pharmaceutical companies in India on contract manufacturing basis.
  • 2009 - The company set up and operationalised a new business division by name SA-Ford dedicated to toxicology studies. It also set up and operationalised a state-of-the-art API plant at Taloja, near Mumbai, which enables it to offer a wide variety of services to its customers.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.